CRIPTO is expressed in a high percentage of infiltrating breast cancers with nearly 80% of carcinomas staining positive in a panel of 100 tumors, suggesting its involvement across multiple breast cancer subtypes including hormone receptor positive (ER+PR+), Her2+ and triple negative breast cancer (TNBC) [45]. Here, CRIPTO is linked to breast carcinoma.